Search Results - "Taneja, Ankush"

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis by Tolley, Keith, Hutchinson, Michael, You, Xiaojun, Wang, Ping, Sperling, Bjoern, Taneja, Ankush, Siddiqui, Mohammed Kashif, Kinter, Elizabeth

“…Subcutaneous pegylated interferon beta-1a (peginterferon beta-1a [PEG-IFN]) 125 μg every two or four weeks has been studied in relapsing-remitting multiple…”
Get full text

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison by Hutchinson, Michael, Fox, Robert J., Havrdova, Eva, Kurukulasuriya, Nuwan C., Sarda, Sujata P., Agarwal, Sonalee, Siddiqui, Mohd Kashif, Taneja, Ankush, Deniz, Baris

“…Abstract Objective: Currently, direct comparative evidence or head-to-head data between BG-12 (dimethyl fumarate) and other disease-modifying treatments (DMTs)…”
Get full text

Systematic Literature Review of the Economic Burden and Cost of Illness in Patients with Myelofibrosis by Tang, Derek, Taneja, Ankush, Rajora, Preety, Patel, Renu

“…Introduction: Myelofibrosis (MF) is a rare bone marrow cancer classified as a myeloproliferative neoplasm in which bone marrow is replaced by fibrous (scar)…”
Get full text

Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders by Yuasa, Akira, Yonemoto, Naohiro, Kamei, Kazumasa, Murofushi, Toshiaki, LoPresti, Michael, Taneja, Ankush, Horgan, Jake, Ikeda, Shunya

“…Introduction In light of the lack of an agreed international standard for how to conduct cost-effectiveness analyses (CEAs), including cost–utility analyses…”
Get full text

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review by Tang, Derek, Taneja, Ankush, Rajora, Preety, Sly, Indeg, Davison, Niall James

“…Introduction: Myelofibrosis (MF) is a rare bone marrow cancer characterized by bone marrow fibrosis and abnormal cytokine expression, often leading to…”
Get full text

Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer by McCrea, Charles, Hettle, Robert, Gulati, Poonam, Taneja, Ankush, Rajora, Preety

“…Two poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are approved for patients with germline BRCA-mutated (gBRCAm) HER2-negative…”
Get full text

MPN-115: Indirect Treatment Comparisons (ITCs) of the Effect of Fedratinib Versus Ruxolitinib (RUX) on Spleen Volume for Patients with Myelofibrosis (MF) and No Prior RUX Treatment by Tang, Derek, Taneja, Ankush, Smith, Sarah, Wu, Chengqing (Alan), Rose, Shelonitda

“…Since 2011, there have been a limited number of treatment options for patients with MF, including allogeneic stem cell transplantation and RUX, a JAK…”
Get full text

Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis by Liang, Xieer, Fan, Rong, Sun, Jian, Shaikh, Javed, Taneja, Ankush, Gupta, Subhajit, Hamed, Kamal

“…Introduction A comprehensive and up-to-date network meta-analysis (NMA) helps to determine the comparative efficacies of nucleos(t)ide analogs (NAs) in…”
Get full text

Systematic Literature Review and Network Meta-Analysis of Pegylated Interferon Beta-1a and Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis (P7.234) by Tolley, Keith, Hutchinson, Michael, Pachner, Andrew, Kinter, Elizabeth, Sperling, Bjorn, You, Xiaojun, Wang, Ping, Taneja, Ankush, Siddiqui, Mohd. Kashif

“…Abstract only…”
Get full text

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: e0127960 by Tolley, Keith, Hutchinson, Michael, You, Xiaojun, Wang, Ping, Sperling, Bjoern, Taneja, Ankush, Siddiqui, Mohammed Kashif, Kinter, Elizabeth

“…Subcutaneous pegylated interferon beta-1a (peginterferon beta-1a [PEG-IFN]) 125 mu g every two or four weeks has been studied in relapsing-remitting multiple…”
Get full text